Acta Scientific Clinical Case Reports

Case ReportVolume 3 Issue 6

POEMS Syndrome - A Case Report

Vaibhav Mathur*, Angad Kumar, Maaz Khan and Gita Bipin Chandra

Department of Neurology, SMS Medical College, Jaipur, India

*Corresponding Author: Vaibhav Mathur, Department of Neurology, SMS Medical College, Jaipur, India.

Received: March 21, 2022; Published: May 5, 2022

Abstract

The acronym “POEMS syndrome”, also known as Crow-Fukase disease, stands for Polyneuropathy, Organomegaly, Endocrinopathy, M-Protein, and Skin changes. It is a rare multisystem disorder, which may take several years to evolve fully, and patients suffer undiagnosed for long [1]. The combination of symptoms and signs is highly complex and some of the features are detected at sub-clinical level requiring high level of suspicion [2]. The clinical data on POEMS is still evolving with only a few case reports from India.

We herein report case of a 38-year-old male with peripheral neuropathy and ascites, which on later work up was diagnosed as POEMS syndrome in accordance with its diagnostic criteria [3-5]. Noteworthy, that the patient later also developed pulmonary Koch’s. The case report is meant to enlighten the readers regarding the clinical spectrum of this uncommon entity and encourage appropriate investigations to confirm the diagnosis in scenarios of multisystem affection.

Keywords: POEMS Syndrome; Ascites; Plasma

Bibliography

  1. Dispenzieri A., et al. “POEMS syndrome: definitions and long-term outcome”. Blood7 (2003): 2496-2506.
  2. Bardwick PA., et al. “Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes: the POEMS syndrome. Report on two cases and a review of the literature”. Medicine4 (1980): 311-322.
  3. Dispenzieri A. “POEMS syndrome: 2014 update on diagnosis, risk-stratification, and management”. American Journal of Hematology2 (2014): 214-223.
  4. Del Río Prado AF., et al. “Male aged 31 years with polyneuropathy, prostration and hypogonadism”. Gaceta medica de Mexico 151 (2015): 256-259.
  5. Li J and Zhou D B. “New advances in the diagnosis and treatment of POEMS syndrome”. British Journal of Haematology3 (2013): 303-315.
  6. Nasu S., et al. “Different neurological and physiological profiles in POEMS syndrome and chronic inflammatory demyelinating polyneuropathy”. Journal of Neurology, Neurosurgery, and Psychiatry5 (2012): 476-479.
  7. Nakanishi T., et al. “The Crow-Fukase syndrome: a study of 102 cases in Japan”. Neurology6 (1984): 712-720.
  8. Kastritis E., et al. “Angiogenetic factors and biochemical markers of bone metabolism in POEMS syndrome treated with high-dose therapy and autologous stem cell support”. Clinical Lymphoma and Myeloma1 (2006): 73-76.
  9. Cai Q Q., et al. “Efficacy and safety of low-dose lenalidomide plus dexamethasone in patients with relapsed or refractory POEMS syndrome”. European Journal of Haematology4 (2015): 325-330.

Citation: Vaibhav Mathur. “POEMS Syndrome - A Case Report". Acta Scientific Clinical Case Reports 3.6 (2022): 15-17.

Copyright: © 2022 Vaibhav Mathur. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is May 30, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US